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  30 
ABSTRACT 31 
A hallmark of acute respiratory distress syndrome (ARDS) is pulmonary vascular 32 
permeability.  In these settings, loss of barrier integrity is mediated by cell-contact 33 
disassembly and actin-remodelling.  Studies into molecular mechanisms responsible for 34 
improving microvascular barrier function are therefore vital in the development of 35 
therapeutic targets for reducing vascular permeability in ARDS.  The sweet taste receptor, 36 
T1R3 is a GPCR, activated following exposure to sweet molecules, to trigger a gustducin-37 
dependent signal cascade.  In recent years, extraoral locations for T1R3 have been identified 38 
however, no studies have focused on T1R3 within the vasculature.  We hypothesise that 39 
activation of T1R3, in the pulmonary vasculature, plays a role in regulating endothelial barrier 40 
function in settings of ARDS.   41 
Our study demonstrated expression of T1R3 within the pulmonary vasculature, with a 42 
drop in expression levels following exposure to barrier disruptive agents.  Exposure of lung 43 
microvascular endothelial cells to the intensely sweet molecule, sucralose, attenuated LPS- 44 
and thrombin-induced endothelial barrier dysfunction.  Likewise, sucralose exposure 45 
attenuated bacteria-induced lung edema formation in vivo.  Inhibition of sweet taste 46 
signalling, through zinc sulfate, T1R3 or G-protein siRNA, blunted the protective effects of 47 
sucralose on the endothelium.  Sucralose significantly reduced LPS-induced increased 48 
expression or phosphorylation of key signalling molecules, Src, PAK, MLC2, HSP27 and 49 
p110αPI3K.    50 
Activation of T1R3, by sucralose, protects the pulmonary endothelium from 51 
edemagenic agent-induced barrier disruption, potentially through abrogation of 52 
Src/PAK/p110αPI3K-mediated cell-contact disassembly and Src/MLC2/HSP27-mediated 53 
actin-remodelling.  Identification of sweet taste sensing in the pulmonary vasculature may 54 
represent a novel therapeutic target to protect the endothelium in settings of ARDS. 55 
  56 
INTRODUCTION 57 
Acute respiratory distress syndrome (ARDS) is a major cause of morbidity and 58 
mortality in patients suffering from several predisposing factors such as trauma, sepsis and 59 
pneumonia.  The syndrome occurs when vascular fluid and protein leak across the pulmonary 60 
microvascular endothelium into the alveolar air space, causing pulmonary edema formation 61 
which is characteristic of the disease.  Respiratory failure then occurs as a result of decreased 62 
gas exchange and lung compliance, and initiation of inflammatory cascades (79). Thus a key 63 
hallmark of ARDS is permeability of the pulmonary microvascular endothelium to vascular 64 
fluid and protein. 65 
Vascular permeability is regulated through several mechanisms depending on the 66 
stimulus however each mechanism results in breakdown of cell-cell contacts and actin 67 
remodelling.  Permeability of the monolayer occurs through disruption of cell-cell contacts, 68 
maintained by the adherens junction complex, and an increase in actin-myosin contractility 69 
(39, 40, 77).  In the case of lipopolysaccharide (LPS), an endotoxin from gram-negative 70 
bacteria, endothelial permeability is mediated through its binding to toll-like receptor 4. The 71 
resulting Src-dependent signalling cascade leads to phosphorylation of both VE-cadherin and 72 
myosin light chain-2 (MLC2) (65, 71).  Furthermore, expression of the heat shock protein 73 
families, HSP27, HSP 70 and HSP 90, correlates with increased vascular permeability (5, 32, 74 
36).  Targeting of these molecular mechanisms has been shown to attenuate LPS-induced 75 
pulmonary edema formation in vivo (3, 15), indicating the potential role for these molecules 76 
in settings of ARDS.   77 
Members of the bitter taste receptor family, and their signalling effectors, have been 78 
identified in pulmonary solitary chemosensory cells (SCCs) (24, 37, 62, 67, 76), ciliated 79 
epithelial cells (64), and smooth muscle cells lining the airways (20).  In pulmonary smooth 80 
muscle, 21 of the 25 members of the bitter taste receptor family have been identified with 81 
bitter taste agonists leading to vasodilation and bronchodilation (10, 20).  While studies have 82 
identified other members of the taste receptor family in solitary chemosensory cells (SCCs), 83 
no functional output has been previously described (74).  In recent years, sweet taste 84 
receptors have also been identified in extraoral locations, such as pancreatic beta cells, 85 
adipocytes and cardiomyocytes (6), however they have not been previously identified in the 86 
vasculature.  Sweet taste is mediated by the G-protein coupled receptor (GPCR), T1R3, which 87 
can form a homodimer or a heterodimer with T1R2 (56).   Sweet taste receptors are activated 88 
upon binding of intensely sweet molecules, such as artificial sweeteners, at low 89 
concentrations (<1 mM) or glucose at high concentrations (>300 mM) (44).  The consumption 90 
of artificial sweeteners has increased in recent years, with the concentration in diet soda 91 
ranging from 150 to 500 µM (25).  In humans, while the majority of artificial sweeteners 92 
consumed are excreted in faeces, a significant proportion are absorbed by the small intestine, 93 
identified within the circulation (plasma) and excreted in the urine as a non-metabolized 94 
molecule (60, 72).  Therefore it is likely that, following consumption of a diet high in artificial 95 
sweeteners, the vasculature is exposed to high levels of these intensely sweet molecules. 96 
In the studies presented here, we demonstrate, for the first time, the presence of the 97 
sweet taste receptor T1R3 in the pulmonary endothelium.  Expression of the receptor was 98 
demonstrated to be modulated by barrier-disruptive agents however stimulation of T1R3, 99 
with the intensely sweet artificial molecule sucralose, attenuates thrombin- and LPS-induced 100 
endothelial monolayer permeability.  Furthermore, in vivo exposure to sucralose attenuates 101 
lung edema formation induced by Pseudomonas aeruginosa. Our studies show that sucralose-102 
mediated protection of the endothelial barrier is dependent on components of the sweet 103 
taste sensing pathway.  Interestingly, exposure to high glucose does not protect the 104 
pulmonary endothelium.  Finally, we implicate a role for HSP27, p110αPI3K, MLC2, Src and 105 
PAK in sucralose-mediated protection of the pulmonary endothelium.  Our studies 106 
demonstrate that sweet taste sensing at the pulmonary endothelium plays a key role in 107 
barrier function.  Stimulation of the sweet taste receptor may represent a novel target in the 108 
treatment of ARDS. 109 
 110 
  111 
METHODS 112 
Cell lines and reagents 113 
TRIzol and Superscript II (Invitrogen).  Rat lung microvascular endothelial cells (LMVEC; 114 
Vec Technologies, Rensselaer, NY) were cultured in MCDB-131 media (Vec Technologies) and 115 
used between passages 3 and 9.  LPS (endotoxin) from Escherichia coli serotype 011:B4, 116 
recombinant VEGF protein and thrombin were purchased from Sigma-Aldrich (St. Louis, MO, 117 
USA).  Pseudomonas aeruginosa strain 103 (PA103) was a kind gift from Dr. Troy Stevens 118 
(University of South Alabama, Mobile, AL, USA). Gustducin (GNAT3) and gustducin siRNA were 119 
purchased from Origene (Rockville, MD, USA).  T1R3 (Tas1R3) and Gαq siRNA were purchased 120 
from Santa Cruz Biotechnology (Santa Cruz, CA, USA). 121 
 122 
In vivo studies 123 
LPS or vehicle (saline) was administered to non-anesthetized, adult male 8- to 10-wk-124 
old C57BL/6 mice via a single injection at different doses (1, 2.5 and 5 mg/kg i.p.). At 24 h 125 
following intraperitoneal injection of LPS or vehicle into mice, lungs were removed for 126 
homogenization.  Untreated male Sprague-Dawley rats were euthanized at 8 weeks and both 127 
lungs and jejunal segments was isolated and stored in RNAlater (Thermo Scientific, Waltham, 128 
MA, USA) at −80 °C. 129 
Mice were exposed to sucralose (1 g/kg) by oral gavage once a day for 1 week. At end-130 
point, live gram-negative bacteria P. aeruginosa (PA103) or PBS vehicle was administered via 131 
a single intratracheal injection [106 colony-forming units (CFUs)]. At 4 h following PA103 132 
administration, wet and dry lung weights were taken. 133 
 134 
All animal experimental protocols were approved by the Institutional Animal Care and 135 
Use Committees of the Providence Veterans Affairs Medical Center and Brown University and 136 
comply with the Health Research Extension Act and U.S. Public Health Service policy. 137 
 138 
RT-PCR 139 
Total RNAs were extracted from rat lung, jejunum and cultured LMVECs using the 140 
TRIzol reagent (Thermo Scientific, Waltham, MA, USA) as per the manufacturer’s instructions.  141 
RNA was purified using the acid phenol/chloroform system and reverse transcribed using 142 
SuperScriptII (Thermo Scientific, Waltham, MA, USA) and T1R3 transcripts were measured 143 
with β-actin (GenBank accession number NM_031 144; forward 937-955, reverse 1223-1208) 144 
used as the house-keeping gene as described previously (8).  Expression of the Tas1r3 gene 145 
was measured using specific intron-spanning primers which were designed from the 146 
sequences published for rat (GenBank accession number NM_130818.1; forward 2107-2126, 147 
reverse 2327-2308).  Relative gene expression level was analysed, for each sample, using the 148 
ΔCt method where ΔCt = (CtTas1r3 – Ctβ-actin) corresponding to the detected threshold cycles for 149 
the target gene and β-actin control. 150 
 151 
Western blotting 152 
LMVEC were exposed to LPS (1 µg/ml) or sucralose (0.1 mM) for 24 hours. Cells were 153 
then lysed with RIPA buffer, resuspended in Laemmli buffer and subjected to immunoblot 154 
analysis. Individual lobes of mouse lungs were homogenized in buffer [20 mM 4-(2-155 
hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES) (pH7.9), 1.5 mM NaCl, 0.25 M 156 
sucrose, 0.2 mM EDTA, 200 mM PMSF, 0.5 mM DTT, and 1.5 mM MgCl2] for 2 min and 157 
subjected to immunoblot analysis. Immunoblot analyses were performed on 10% SDS-PAGEs 158 
using a range of primary antibodies (table 1) at a dilution of 1:1000, except vinculin (1:5000), 159 
and secondary antibody dilutions of 1:5000.  All samples were run on the same immunoblot 160 
for each protein analysed.  Antibody specificity verification was assessed based on previous 161 
publications (included in table 1) or with siRNA knockout studies (Figure 5).   162 
 163 
Endothelial monolayer permeability 164 
Changes in endothelial monolayer permeability were assessed using the electrical cell 165 
impedance sensor (ECIS) technique (Applied Biophysics, Troy, NY), as previously described 166 
(16, 29). For analysis of monolayer permeability LMVEC were seeded to confluence onto 167 
collagen-coated electric cell-substrate impedance sensing arrays. For knockdown 168 
experiments, LMVECs were transiently transfected with T1R3, Gαq or gustducin siRNA 169 
duplexes (300 nM), or ns, scrambled control, using the Amaxa (Allendale, NJ, USA) 170 
electroporation technique as described previously (15).  Monolayers were treated with either 171 
sucralose (0.1 mM), glucose (5.5 mM, 11 and 25 mM) or vehicle (H2O) in the presence and 172 
absence of VEGF (50 ng/ml), thrombin (2 U/ml), LPS (1 µg/ml) or zinc sulfate (0.7 mM).  173 
Addition of treatments were made at the same time and resistance was measured over time.   174 
 175 
Statistical analysis 176 
For three or more groups, differences among the means were tested for significance 177 
in all experiments by ANOVA with Fisher’s least significance difference test. Significance was 178 
reached when p < 0.05. Values are mean ± standard deviation (SD). 179 
 180 
 181 
  182 
RESULTS 183 
Sweet taste receptor, T1R3, is expressed at the pulmonary endothelium 184 
Sweet taste receptor T1R3 is the key component of the sweet taste complex – T1R3 is 185 
necessary for the heterodimeric complex but can also form a homodimer for sweet taste 186 
sensing (19, 50, 56).  In addition to the oral cavity, high expression of T1R3 mRNA (TAS1R3) 187 
and protein has been found in the small intestine, in particular the jejunum (41).  mRNA 188 
expression levels of TAS1R3 in rat lungs and LMVEC were comparable to the positive control 189 
rat tissue (jejunum) (Figure 1a).  To assess the link between sweet taste receptor and ARDS, 190 
protein expression of T1R3 was studied in LMVEC following exposure (24 h) to the barrier 191 
disruptive agents LPS, VEGF and thrombin, and in mouse lungs following exposure to LPS (4 192 
h).  In LMVEC, T1R3 protein levels were significantly reduced, to a similar degree, in the 193 
presence of all three agonists (Figure 1b).  Expression of T1R3 in mouse lungs was unaffected 194 
at low concentrations of LPS (1 and 2.5 mg/kg) however at 5 mg/kg, where lung injury and 195 
vascular leak are observed (13, 15), T1R3 expression was significantly reduced (Figure 1c). 196 
This data demonstrates the presence of T1R3 in the lung microvasculature, and implicates 197 
sweet taste sensing in endothelial barrier function. 198 
 199 
Artificial sweetener sucralose attenuates  barrier disruption in vitro and in vivo 200 
The sweet taste receptor complex is activated by low concentrations of intensely 201 
sweet molecules or high concentrations of sugars (51).  Our previous studies demonstrate 202 
that endothelial permeability is closely related to adherens junction formation, with increased 203 
VE-cadherin surface levels observed in barrier protective settings (15). Therefore we next 204 
assessed whether activation of T1R3 with the artificial sweetener sucralose, at concentration 205 
close to EC50 (51), has an effect on endothelial barrier function and VE-cadherin surface 206 
expression.  LMVEC exposed to sucralose displayed no change in endothelial monolayer 207 
resistance (Figure 2a, 2b, 3a and 3b) or VE-cadherin surface expression (Figure 2c and 3c).  208 
Interestingly, thrombin-induced permeability and loss of VE-cadherin surface expression was 209 
significantly attenuated by concomitant exposure of LMVEC to sucralose (Figure 2).  Likewise, 210 
sucralose attenuated LPS-induced permeability and decrease in VE-cadherin surface levels 211 
(Figure 3).   We next sought to establish whether sucralose exerted a protective effect on in 212 
vivo lung edema formation (wet-to-dry lung weight).  Mice were exposed to a daily oral dose 213 
of sucralose over a 1 week period, followed by exposure to P. aeruginosa (PA103) as a model 214 
for acute lung injury.  Similar to in vitro findings, sucralose exposure significantly attenuated 215 
PA103-induced lung edema formation in vivo (Figure 3d).  Interestingly, sucralose exposure 216 
in the absence of PA103 had no effect on lung edema formation.  Interestingly, both LPS- and 217 
thrombin-induced permeability in vitro and PA103-induced edema formation in vivo was not 218 
completely reversed by sucralose however the artificial sweetener did result in surface 219 
expression levels of VE-cadherin returning to baseline levels (Figure 2 and 3).   220 
We next assessed whether glucose regulates endothelial barrier function in a similar 221 
manner.  LMVEC were exposed to increasing concentrations of glucose from fasting levels 222 
(5.5 mM) to hyperglycaemic levels (25 mM), with an osmotic control of mannose used for the 223 
high glucose concentration, in the presence and absence of LPS.  High glucose (25 mM), but 224 
not lower glucose concentrations or mannose, significantly increased endothelial 225 
permeability and decreased VE-cadherin surface levels under baseline conditions (Figure 4a 226 
and b).  LPS-induced permeability and decreased VE-cadherin surface levels was significantly 227 
exacerbated in the presence of high glucose, but not lower glucose concentrations or 228 
mannose (Figure 4a and b).  Interestingly, exposure of LMVEC to sucralose significantly 229 
increased protein levels of T1R3, whilst high glucose had no effect on expression of the sweet 230 
taste receptor (Figure 4c).   231 
Taken together, these data indicate that the intensely sweet molecule sucralose, but 232 
not high physiological levels of glucose, regulates T1R3 to protect the pulmonary endothelium 233 
against barrier disruption.   234 
 235 
Barrier-protective effect of sucralose is mediated through sensing by the sweet taste 236 
receptor 237 
 To study whether sucralose acts on the endothelial monolayer in a T1R3-dependent 238 
manner, the next experiments utilised inhibitors of the sweet taste receptor pathway.  239 
Molecular and chemical inhibition of T1R3 was performed using siRNA knockdown (Figure 5a) 240 
and exposure to zinc sulfate (Figure 5b) a chemical inhibitor of sweet taste receptor (23, 38). 241 
Endothelial permeability was assessed in the presence and absence of LPS and sucralose.  242 
Interestingly, attenuation of LPS-induced permeability by sucralose was significantly blocked 243 
by molecular (Figure 5aii) and chemical (Figure 5b) inhibition of T1R3.  In the presence of LPS 244 
alone, T1R3 inhibition had no impact on endothelial permeability (Figure 5a and b).  Molecular 245 
inhibition of gustducin, a key signalling molecule downstream of T1R3 (53), was performed 246 
using siRNA knockdown (Figure 5ci).  Knockdown of gustducin, had no effect on endothelial 247 
permeability in settings of either LPS or sucralose exposure (Figure 5cii).  Molecular inhibition 248 
of gustducin significantly abrogated sucralose-mediated protection of LPS-induced 249 
permeability (Figure 5cii).  The G protein, Gαq, which is highly expressed in the lung has also 250 
been identified to play a role in sweet taste sensing (75, 80).  Molecular inhibition of Gαq was 251 
performed in LMVEC using siRNA (Figure 5di).  Protection of LPS-induced permeability, by 252 
sucralose, was reduced by 21% following knockdown of Gαq (Figure 5d).  These data indicate 253 
that sucralose exerts a protective effect on the endothelium, in settings of barrier disruption, 254 
through regulation of the sweet taste receptor and the downstream  signalling pathway. 255 
 256 
Sucralose attenuates LPS-induced elevated HSP27 and p110α and activation of MLC2, Src 257 
and PAK 258 
 To assess the molecular mechanism through which sucralose exerts an effect on LPS-259 
induced signalling, key regulators of the adherens junction and endothelial barrier function 260 
were assessed for expression and activity.  Phosphorylation of kinases FAK, p38, ERK, PAK, 261 
p70 and Src (15, 28), phosphatase SHP2 (14), filament proteins VASP and cofilin (59, 67), and 262 
MLC2 (7) were measured at phosphorylation sites relevant to protein activity (Table 1).  263 
Expression of heat shock proteins HSP27, 70 and 90 (11, 36, 45) and the p110αPI3K (9) were 264 
also assessed.  Sucralose treatment, in the absence of LPS, had no effect on phosphorylation 265 
or expression of any regulator molecule (Figure 6 and 7).  Phosphorylation of MLC2, Src and 266 
PAK by LPS was significantly attenuated by exposure to sucralose (Figure 6 a, 6b and 6c), 267 
whereas phosphorylation of other key regulators was unaffected by sucralose (Figure 7a-g).  268 
Unlike MLC2 and Src, in the presence of sucralose and LPS, phosphorylation of PAK did not 269 
return to baseline conditions (Figure 6a, 6b and 6c).  Expression levels of HSP27 and 270 
p110αPI3K were increased following exposure to LPS however this effect was abrogated by 271 
sucralose (Figure 6d and 6e).  This effect was not observed in the other heat shock proteins, 272 
HSP70 and 90 (Figure 7h and 7i). Taken together, these data indicate that sucralose may 273 
attenuate LPS-induced permeability through inhibition of key barrier disruptive signaling 274 
molecules. 275 
 276 
  277 
DISCUSSION 278 
In the present study we demonstrate, for the first time, the localisation and function 279 
of the sweet taste receptor at the pulmonary endothelium.  Our research identified the 280 
expression of T1R3 in the lung and microvascular endothelial cells, with reduced protein levels 281 
in response to the barrier-disruptive agents LPS, thrombin and VEGF.  We observed that 282 
activation of T1R3, by exposure to the artificial sweetener sucralose, protects the 283 
microvasculature in vitro and in vivo against barrier disruptive agents, through a sweet taste 284 
receptor-dependent pathway.  Lastly, we implicated a role for sucralose in attenuating LPS-285 
mediated Src, PAK, MLC2, HSP27 and p110αPI3K signalling.  Therefore the stimulation of 286 
T1R3, by artificial sweetener sucralose, represents a novel mechanism through which the 287 
pulmonary microvasculature is regulated.   288 
 The sweet taste receptor, T1R3, was first identified at the Sac genetic locus, which 289 
regulates sweet taste sensitivity, with expression observed in a subset of taste cells within the 290 
oral cavity (52, 54).   Interestingly, T1R3 has recently been identified in extraoral locale, 291 
including the pancreatic beta cell, adipocytes and the bladder, however to date, no studies 292 
have assessed T1R3 in the vasculature (23, 55, 66, 73).  Our study identifies T1R3 mRNA 293 
expression in the rat lung and microvascular endothelial cells.  Interestingly, mRNA levels of 294 
both were similar to those observed in the jejunum segment of the small intestine.  Studies 295 
by others and us have identified T1R3 in different cell types within the small intestine, 296 
predominantly the jejunum, where activation of the receptor is linked to altered glucose 297 
metabolism in patients with metabolic diseases (8, 47, 49, 69).  Therefore T1R3 expression in 298 
the pulmonary vasculature is likely to be at a physiologically significant level.  Endothelial cell 299 
protein expression of T1R3 was reduced by the barrier disruptive agents LPS, thrombin and 300 
VEGF.  This was mirrored in the mouse lung where decreased T1R3 levels were noted 301 
following LPS treatment.  Interestingly, at low doses of LPS, where no pulmonary edema is 302 
observed (data not shown), T1R3 expression is not significantly affected however at 5 mg/kg 303 
dose, where pulmonary edema is observed (13, 15), T1R3 expression was significantly 304 
reduced.  Therefore it is likely that T1R3 expression plays a role in pulmonary endothelial 305 
barrier maintenance in vivo and in vitro.  Indeed, following exposure to sucralose, which 306 
activates T1R3, barrier permeability caused by LPS and thrombin was attenuated.  These 307 
findings were mirrored in an in vivo model of lung injury (P. aeruginosa), with sucralose 308 
exposure blocking lung edema formation. The in vitro protective role of sucralose was blocked 309 
following inhibition of sweet taste sensing, either by acting on the receptor via zinc sulfate 310 
(23, 38) or siRNA knockdown of T1R3 or downstream G proteins gustducin and Gαq (53, 75).  311 
Inhibition of T1R3, through siRNA or zinc sulfate, attenuated the protective effect of sucralose 312 
on the endothelial barrier. The artificial sweetener is therefore acting through the sweet taste 313 
receptor to initiate a protective signalling response.  Interestingly, Gαq inhibition did not 314 
completely blunt sucralose-mediated protection as seen in gustducin inhibition.  It is 315 
therefore likely that gustducin, but not Gαq, is essential for T1R3-mediated signalling in the 316 
pulmonary endothelium.     317 
 Signalling mechanisms mediated by activated T1R3 vary depending on the cell type.  318 
In the pancreatic beta cell, sweetener-T1R3 binding results in insulin release mediated by 319 
elevated intracellular calcium levels (55) whilst in the adipocyte, Akt phosphorylation was 320 
noted to play a role in the stimulation of adipogenesis (66).  In the pulmonary endothelium, 321 
studies presented here link the phosphorylation of Src, PAK and MLC2, and increased 322 
expression of HSP27 and p110αPI3K, with sucralose-mediated protection from LPS.  Previous 323 
studies have indicated a key role for Src and PAK phosphorylation, and p110αPI3K expression, 324 
in the breakdown of the pulmonary endothelium through dissolution of the adherens junction 325 
(9, 12, 15, 28) and in HSP27 and MLC2-mediated actin remodelling associated with barrier 326 
disruption (27, 32, 65, 71).  Interestingly, other key regulators of the pulmonary endothelium, 327 
such as the filament proteins cofillin and VASP (59, 67) are phosphorylated by LPS but 328 
unaffected by sucralose.  Thus, upon activation, T1R3 acts on a limited range of signalling 329 
molecules to regulate endothelial barrier function.  The link between signalling downstream 330 
of T1R3 and Src/PAK/p110αPI3K and HSP27/MLC2 is unclear at present however it is possible 331 
that PLCβ2 recruitment, following release of gustducin and Gαq, triggers the activation of 332 
kinases such as the inhibitory Src kinase Csk (48, 81).  This in turn may regulate downstream 333 
molecules to protect the endothelial barrier from LPS-induced disruption.  However further 334 
studies are necessary to identify and understand the molecular mechanisms through which 335 
T1R3 downstream signalling regulates Src/PAK/p110αPI3K and HSP27/MLC2 within the 336 
pulmonary endothelium.  337 
Sucralose is an intensely sweet, commercially-available artificial sweetener with an 338 
estimated ‘sweetness’ index of 600-times compared to sucrose (57).  Sucralose, like many 339 
artificial sweeteners, stimulates the sweet taste receptor at low concentrations (<1 mM) (44).  340 
At glucose concentrations needed to stimulate T1R3 (>300 mM), endothelial cells are not 341 
viable due to hyperosmolarity (1, 21).  We demonstrate that, at a physiologically relevant high 342 
concentration of glucose (25 mM), vascular permeability was increased.  Similar to previous 343 
studies, we also observed that high glucose exacerbates LPS-mediated barrier disruption (46) 344 
therefore the protective effect of T1R3 activation, with sucralose, cannot be mimicked by 345 
glucose. Furthermore, whilst this study focused on the use of sucralose to activate T1R3, 346 
different artificial sweeteners demonstrate varying ability to bind T1R3 and stimulate 347 
downstream signalling (56).  It is therefore possible that the level of pulmonary barrier 348 
protection exhibited by the sweetener is dependent on the type of sweet molecule used. 349 
There is significant controversy regarding the benefit of artificial sweetener 350 
consumption in the diet.  At present, a large proportion of the population consumes artificial 351 
sweeteners, such as sucralose, at high levels (25) however clinical studies do not record any 352 
pulmonary responses in this population.  Interestingly, our studies show that exposure of the 353 
microvasculature to sucralose, in the absence of LPS, has no effect on barrier function or on 354 
the expression or activation of key signalling molecules which regulate the endothelium.  355 
Therefore it is possible that stimulation of T1R3, by artificial sweeteners, only plays a 356 
physiological role in settings of vascular permeability.  This represents the potential for 357 
artificial sweeteners to act as a novel therapeutic agent in diseases such as ARDS, however 358 
further studies are necessary to assess the long-term effect of artificial sweeteners on the 359 
pulmonary vasculature.   Whilst the present study only assessed T1R3 expression, as it is the 360 
predominant sweet taste receptor which homodimerises to sense sweet molecules, T1R2 can 361 
form a heterodimer with T1R3 and form a sweet taste receptor complex (56).  Furthermore, 362 
T1R3 can heterodimerise with T1R1 to form an umami taste receptor complex.  As our study 363 
demonstrates a significant protective effect played by the sweet taste receptor in the 364 
pulmonary endothelium, it would be interesting to assess other taste sensing complexes 365 
within the vasculature.  In fact, previous studies have implicated that stimulation of the bitter 366 
taste receptor family (T2R) in airway smooth muscle and epithelial cells, with bitter taste 367 
agonists, stimulates bronchodilation and ciliary beat frequency respectively (20, 64).  Bitter 368 
agonists are currently under scrutiny as a treatment for asthma and COPD patients (42, 61, 369 
68) however studies are yet to assess the presence or activation of bitter taste receptors 370 
within the pulmonary vasculature.  Our studies demonstrate that sweet taste agonists block 371 
the barrier disruptive effects of LPS on the pulmonary endothelium.  There is therefore the 372 
potential for taste agonists to play a major role in various lung diseases in the future. 373 
 374 
 375 
 376 
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FIGURE LEGENDS 630 
 631 
Figure 1: Expression of the sweet taste receptor, T1R3, at the pulmonary endothelium is 632 
regulated by barrier disruptive agents. Panel a: mRNA expression of the T1R3 gene, Tas1r3, 633 
in rat lung and jejunum tissue and cultured rat LMVEC.  Gene expression is relative to the 634 
housekeeping gene, β-actin, and normalized to the positive control jejunum tissue.  n = 6.  635 
Panel b and c: Protein expression of T1R3 in: (b) cultured rat LMVEC exposed to LPS (1 µg/ml), 636 
thrombin (2 U/ml) or VEGF (50 ng/ml) for 24 hours and (c) homogenates of lungs from 637 
C57/BL6 mice exposed to varying doses of LPS (0 - 5 mg/kg).  n = 5.   A representative blot (i) 638 
and densitometry relative to the load control, β-actin (ii) are shown.  Data is expressed as 639 
mean ± S.D. *p<0.05 versus vehicle. 640 
 641 
Figure 2: Stimulation of the artificial sweetener sucralose attenuates thrombin-induced 642 
barrier disruption and VE-cadherin internalisation.  Panels a and b: Changes in rat LMVEC 643 
endothelial monolayer resistance were measured using ECIS in the presence (closed symbols) 644 
and absence (open symbols) of thrombin (2 U/ml).  Monolayers were exposed to sucralose 645 
(0.1 mM) (triangle symbols), or vehicle (H2O) (square symbols) at the same time as thrombin.  646 
Permeability is shown as (a) an experimental trace, normalised to the addition of thrombin 647 
and sucralose (arrow), and (b) drop in endothelial resistance measured at 12 minutes post-648 
thrombin and sucralose treatment.  n = 5. Panel c: Cell surface expression of VE-cadherin was 649 
determined, with whole-cell indirect ELISA using chemiluminescence, following exposure to 650 
thrombin and sucralose as per (a).  n = 6. Data is expressed as mean ± S.D. *p<0.05 versus 651 
vehicle for thrombin, #p<0.05 vs vehicle for sucralose. 652 
 653 
Figure 3: Stimulation of the artificial sweetener sucralose attenuates LPS-induced barrier 654 
disruption and VE-cadherin internalisation in vitro and bacteria-induced edema formation 655 
in vivo. Panels a and b: Changes in rat LMVEC endothelial monolayer resistance were 656 
measured using ECIS in the presence (closed symbols) and absence (open symbols) of LPS (1 657 
µg/ml).  Monolayers were exposed to sucralose (0.1 mM) (triangle symbols), or vehicle (H2O) 658 
(square symbols) at the same time as LPS.  Permeability is shown as (a) an experimental trace, 659 
normalised to the addition of LPS and sucralose (arrow), and (b) drop in endothelial resistance 660 
measured at 10 hours.  n = 5. Panel c: Cell surface expression of VE-cadherin was determined, 661 
with whole-cell indirect ELISA using chemiluminescence, following exposure to LPS and 662 
sucralose as per (a).  n = 6. Panel d: Lung edema formation was determined by measuring 663 
wet-to-dry lung weight ratio in mice following daily gavage of sucralose (1 g/kg) for 1 week 664 
and 4 hour exposure to P. aeruginosa (PA103). n=5-8.  Data is expressed as mean ± S.D. 665 
*p<0.05 versus vehicle for LPS, #p<0.05 vs vehicle for sucralose. 666 
 667 
Figure 4: High glucose exposure increases endothelial barrier permeability and VE-cadherin 668 
internalisation.  Panel a: Changes in rat LMVEC endothelial monolayer resistance (panel a) 669 
were measured using ECIS in the presence (closed bars) and absence (open bars) of LPS (1 670 
µg/ml).  Monolayers were exposed to different concentrations of glucose (5.5, 11 and 25 mM) 671 
or osmotic control mannose (25 mM) at the same time as LPS.  Permeability is shown as drop 672 
in endothelial resistance measured at 10 hours.  n = 5.  Panel b: Cell surface expression of VE-673 
cadherin was determined, with whole-cell indirect ELISA using chemiluminescence, following 674 
exposure to LPS and glucose as per (a). Panel c: Protein expression of T1R3 in cultured rat 675 
LMVEC exposed to sucralose (0.1 mM), glucose (25 mM) or vehicle for both (H2O) for 24 hours.  676 
A representative blot (upper panel) and densitometry relative to the load control, β-actin 677 
(lower panel) are shown.  n = 5. Data is expressed as mean ± S.D. *p<0.05 versus vehicle for 678 
LPS, #p<0.05 versus 5.5 mM control.  679 
 680 
Figure 5: Barrier-protective effect of sucralose is mediated through sensing by the sweet 681 
taste receptor.  Panels a, c and d: Equivalent numbers of rat LMVECs were transiently 682 
transfected with scrambled (300 nM, open bars) or T1R3 (300 nM, closed bars) siRNA (panel 683 
a ii), gustducin (Gus, 300 nM, closed bars) siRNA (panel c ii) or Gαq (300 nM, closed bars) 684 
siRNA (panel d ii).  Following 48 hours, changes in endothelial monolayer resistance were 685 
measured using ECIS in the presence and absence of LPS (1 µg/ml) and sucralose (0.1 mM). 686 
Permeability is shown as drop in endothelial resistance measured at 10 hours (ii).  Knockdown 687 
of endogenous protein was confirmed by immunoblot analysis of lysates from transiently 688 
transfected cells with an antibody specific to T1R3 (panel a i), gustducin (panel c i) and Gαq 689 
(panel d i). Panel b: Monolayer permeability was assessed in the presence and absence of the 690 
sweet taste inhibitor zinc sulfate (0.7 mM).  Changes in endothelial monolayer resistance 691 
were measured using ECIS in the presence and absence of LPS (1 µg/ml) and sucralose (0.1 692 
mM). Permeability is shown as drop in endothelial resistance measured at 10 hours. n = 5-6. 693 
Data is expressed as mean ± S.D. *p<0.05 versus vehicle for LPS, ʎp<0.05 vs vehicle for 694 
sucralose, #p<0.05 versus LPS + vehicle for sucralose. 695 
 696 
Figure 6: Sucralose attenuates LPS-induced elevated HSP27 and p110αPI3K and activation 697 
of MLC2, Src and PAK.  Rat LMVECs were treated in the presence or absence of LPS (1 µg/ml) 698 
and sucralose (0.1 mM) for 24 hours. Phosphorylation of MLC-2 (a), Src (b) and PAK (c) was 699 
assessed in whole-cell lysates by immunoblot analysis with an antibody specific to each 700 
phosphorylated protein.  Blots were stripped and reprobed for total protein expression and 701 
actin as a loading control.  Total protein expression of HSP27 (d) and p110αPI3K (e) was also 702 
assessed in whole-cell lysates, followed strip and reprobe of blots for actin as a loading 703 
control. Representative blots are shown. Non-essential lanes from the HSP27 representative 704 
blot (panel d) have been removed.  n = 6. Data is expressed as mean ± S.D. *p<0.05 versus 705 
vehicle for LPS, #p<0.05 vs vehicle for sucralose. 706 
 707 
Figure 7: Role of sucralose on LPS-mediated signalling is independent of several key 708 
molecules. Rat LMVECs were treated in the presence or absence of LPS (1 µg/ml) and 709 
sucralose (0.1 mM) for 24 hours. Phosphorylation of HSP70 (a), SHP2 (b), ERK (c), FAK (d), 710 
VASP (e), p38 (f) and cofillin (g) was assessed in whole-cell lysates by immunoblot analysis 711 
with an antibody specific to each phosphorylated protein.  Blots were stripped and reprobed 712 
for total protein expression and actin as a loading control.  Total protein expression of HSP70 713 
(h) and HSP90 (i) was also assessed in whole-cell lysates, followed strip and reprobe of blots 714 
for actin as a loading control. Representative blots are shown. n = 6. Data is expressed as 715 
mean ± S.D. *p<0.05 versus vehicle for LPS. 716 
 717 
  718 
TABLE 719 
 720 
Table 1: List of antibodies used for protein phosphorylation (panel a) and expression (panel 721 
b) analysis by Western blot. 722 
 723 
a 724 
Antibody  Company Phospho site 
Phospho-Cofilin Cell Signaling (30) Serine 3  
Phospho-MLC2  Cell Signaling (22) 
Threonine 18 / serine 
19  
Phospho-VASP  Cell Signaling (31) Serine 239 
Phospho-PAK 1/2  Cell Signaling (33) Threonine 423/402 
Phospho-Src  Cell Signaling (4) Tyrosine 416 
Phospho-ERK1/2 Cell Signaling (70) 
Threonine 202 / 
tyrosine 204 
Phospho-p38 Cell Signaling (17) 
Threonine 180 / 
tyrosine 182  
Phospho-p70 
(T389) 
Cell Signaling (78) Threonine 389 
Phospho-FAK 
(Y397) 
Cell Signaling (12) Tyrosine 397  
Phospho-SHP2 
(Y542) 
Santa Cruz (12) Tyrosine 452  
 725 
b 726 
Antibody  Company  
HSP90 BD Biosciences (43) 
FAK BD Bioscience (12) 
HSP70 BD Biosciences (18) 
Cofilin  Cell Signaling (58) 
VASP Cell Signaling (31) 
 727 
 728 
 729 
PAK1 Cell Signaling (4) 
MLC2 Cell Signaling (22) 
ERK1/2 Cell Signaling (35) 
p38 Cell Signaling (17) 
Src Santa Cruz (34) 
SHP2 Santa Cruz (12) 
p70 Santa Cruz (26) 
T1R3 Santa Cruz 
β-actin Santa Cruz (2) 
Gαq Santa Cruz 
p110αPI3K Santa Cruz (82) 
Gustducin Santa Cruz 
HSP27 Santa Cruz (63) 
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